Shares of Alkem Laboratories will be in focus heading into trade on Wednesday after witnessing large block transactions worth around Rs 930 crore on Tuesday. Promoter-linked entities reduced their stake, while several domestic mutual funds and foreign institutional investors emerged as buyers.Data available on the NSE showed that 17.88 lakh shares were traded through the block deals at Rs 5,200 per share, totalling about Rs 930 crore. A combination of domestic and overseas institutional investors picked up the shares. ICICI Prudential Mutual Fund was the largest buyer, acquiring 9.04 lakh shares, followed by HDFC Mutual Fund with 5.1 lakh shares. Other investors participating in the deal included DSP Mutual Fund, Nippon India Mutual Fund, Morgan Stanley Asia Singapore, Goldman Sachs Bank Europe, BNP Paribas Arbitrage, Societe Generale and Edelweiss Mutual Fund.On the selling side, Jayanti Sinha offloaded 12.38 lakh shares, while Samprada & Nanhamati Singh Family Trust sold 5.5 lakh shares. Together, the two entities accounted for the entire 17.88 lakh shares that changed hands in the transaction.In a separate development, Alkem Laboratories on Tuesday launched semaglutide in single-shot pre-filled syringes in India at a starting price of Rs 350, becoming the first company in the country to offer the popular diabetes and weight-management drug in that format.The company received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for managing Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.Alkem Labs Q4 snapshotAlkem Laboratories reported a 40.7% year-on-year increase in pre-exceptional profit to Rs 557.8 crore in Q4FY26, driven by robust growth in both domestic and international businesses along with improved operating leverage.Revenue rose 14.6% year-on-year to Rs 3,603.3 crore. Domestic sales grew 8.8% to Rs 2,324.5 crore, while revenue from international operations jumped 25.4% to Rs 1,222 crore. Net profit after exceptional items, however, declined 22.7% to Rs 236.5 crore, impacted by one-time charges of around Rs 135 crore.Alkem Laboratories remains one of India's leading pharmaceutical companies, with a significant presence across acute therapies, chronic care segments and international markets. The participation of several large domestic mutual funds in the block deal indicates continued institutional interest in established healthcare companies despite ongoing volatility in broader equity markets.Sensex, Nifty today: Catch all the LIVE stock market action here(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)